ABSTRACT
Background Fasting has been shown to be one of the most cost-effective methods to improve cardiometabolic health. We studied a 5-day hypocaloric (∼600 kcal/day) and ketogenic, modified fasting program (MFP) for at-home interventions. We hypothesised that this MFP induces metabolic changes comparable to 5 days of prolonged fasting (75-250kcal/day).
Methods We tested the MFP in a two-arm randomised controlled trial where sixty-four healthy subjects were randomised to MFP or control group. Serum biochemistry analyses and questionnaires allowed for determining effects on cardiometabolic risk factors. Emotional well-being, possible side effects and physical activity were assessed with questionnaires. Biological pathways and metabolic processes were explored with nuclear magnetic resonance blood metabolomics and gut metagenomics analyses.
Results MFP participants (n=32) experienced weight loss (−3.1 ± 1.1 kg) persisting one month after the intervention. The MFP induced significant, but transient reductions, in systolic (−6.4 ± 11.5 mmHg) and diastolic (−4.4 ± 7.7 mmHg) blood pressure, glucose levels, HbA1c and coagulation factors. The MFP led to greater reductions in BMI (p=0.006), diastolic pressure (p = 0.009), cholesterol (p = 0.02), and LDL (p = 0.02) in individuals at risk of cardiometabolic diseases compared to healthy individuals. Total cholesterol, LDL-C and HDL-C levels continued decreasing during food reintroduction. The MFP also increased emotional and physical well-being. Blood metabolomics revealed a significant decrease in chronic inflammation markers. Shotgun metagenomics of the gut microbiome showed trends in the changes in relative abundance of the majority of bacterial species and their genomic repertoire of carbohydrate-active enzymes (CAZymes). This reflected a decrease in families metabolising dietary fibre substrates and an increase in families metabolising host-derived glycan substrates. Comparing MFP effects with a previous cohort’s 5-day prolonged fasting showed similar metabolic changes.
Conclusion This MFP is safe and effectively improves cardiometabolic health and emotional well-being in healthy individuals. It offers comparable metabolic benefits to those observed during 5-day prolonged fasting in a clinic. It is safe to be practised at home, widely accessible and compatible with individuals’ everyday life.
Competing Interest Statement
Authors FG, RM, AH and FWT are employees of the Buchinger Wilhelmi Development and Holding GmbH. Authors SS, SH, RG are employees of lifespin GmbH. The remaining authors declare no competing.
Clinical Trial
NCT05821660
Funding Statement
The study was financed by Buchinger Wilhelmi Development & Holding GmbH. Further funding was provided by the LUMC (LUMC Fellowship to G.Z.), the Health + Life Science Alliance Heidelberg Mannheim through state funds approved by the State Parliament of Baden-Wurttemberg (postdoctoral fellowships to Q.D.) and EMBO postdoctoral fellowship (ALTF 1030-2022 to Q.D.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
). The study protocol was approved by the Ethics Committee of the Medical Association of Baden-Wurttemberg, Stuttgart, Germany (approval number: F-2023-014). The study was registered at ClinicalTrials.gov (NCT05821660) prior to the start of patient recruitment.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
DATA AVAILABILITY
Raw metagenomic data will be made available upon acceptance of the manuscript under accession number PRJEB75353 at ENA.
